ArticleTranslational cancer research2026
Development and validation of nomograms for predicting overall survival and cancer-specific survival in female gastric signet-ring cell carcinoma: a SEER database analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric signet-ring cell carcinoma (GSRC) shows significant gender differences in terms of incidence and clinical manifestations. Compared with male patients, female patients are usually diagnosed more frequently and present with diffuse histological types, and have different metastasis patterns. However, the existing GSRC prognostic models are mainly established based on a mixed gender population, which has important limitations. Therefore, this study aimed to develop and validate gender‑specific nomograms to predict overall survival (OS) and cancer‑specific survival (CSS) in female patients with GSRC. Methods: Data of female GSRC patients diagnosed between 2010 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The inclusion criteria were: diagnosis confirmed by the International Classification of Diseases for Oncology, 3 Results: We constructed 1-, 3-, and 5-year prognostic nomograms for OS and CSS in female GSRC patients. In the training cohort, the OS model achieved 1-, 3-, and 5-year areas under the curve (AUCs) of 0.783, 0.855, and 0.867, respectively (C-index =0.755); the corresponding AUCs for the CSS model were 0.758, 0.863, and 0.882 (C-index =0.753). In the validation cohort, the OS model achieved AUCs of 0.828, 0.871, and 0.887 (C-index =0.766), while the CSS model achieved AUCs of 0.777, 0.847, and 0.871 (C-index =0.753). Overall, the calibration curves of the two models were consistent with the diagonal line. DCA indicated a superior net benefit relative to any single variable. K-M analysis demonstrated significantly poorer survival in the high-risk group compared with the low-risk group, underscoring the model's capacity to distinguish distinct prognostic categories. Conclusions: The proposed nomograms provide moderately accurate estimation (C-index: ~0.75) of OS and CSS in females with GSRC, offering a valuable tool for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.